Clinical radioimmunotherapy-the role of radiobiology

Nature Reviews Clinical Oncology

Volumn 8, Issue 12, 2011, Pages 720-734

  Pouget, Jean Pierre ^a   Navarro Teulon, Isabelle ^b   Bardiès, Manuel ^c   Chouin, Nicolas ^b   Cartron, Guillaume ^d   Pèlegrin, André ^b   Azria, David ^b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^b INSERM   (France)

^c CNRS   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; TOSITUMOMAB I 131;

APOPTOSIS; BYSTANDER EFFECT; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; HUMAN; LYMPHOMA; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RADIOBIOLOGY; RADIOIMMUNOTHERAPY;

EID: 82555170240     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.160     Document Type: Review

References (164)

1. Boswell, C. A. & Brechbiel, M. W. Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view. Nucl. Med. Biol. 34, 757-778 (2007).
2. Schaefer, N. G., Huang, P., Buchanan, J. W. & Wahl, R. L. Radioimmunotherapy in non-Hodgkin lymphoma: Opinions of nuclear medicine physicians and radiation oncologists. J. Nucl. Med. 52, 830-838 (2011).
3. Prise, K. M., Schettino, G., Folkard, M. & Held, K. D. New insights on cell death from radiation exposure. Lancet Oncol. 6, 520-528 (2005).
4. Valerie, K. et al. Radiation-induced cell signaling: Inside-out and outside-in. Mol. Cancer Ther. 6, 789-801 (2007).
5. Eriksson, D. & Stigbrand, T. Radiation-induced cell death mechanisms. Tumour Biol. 31, 363-372 (2010).
6. Hernandez, M. C. & Knox, S. J. Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 59, 1274-1287 (2004).
7. Eckerman, K. F. & Endo, A. MIRD Radionuclide Data and Decay Schemes. 2nd edn (Society of Nuclear Medicine, Reston, 2008).
8. Belka, C. et al. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int. J. Radiat. Oncol. Biol. Phys. 58, 542-554 (2004).
9. Milenic, D. E., Brady, E. D. & Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 3, 488-499 (2004).
10. Pouget, J. P. & Mather, S. J. General aspects of the cellular response to low- and high-LET radiation. Eur. J. Nucl. Med. 28, 541-561 (2001).
11. Sgouros, G. et al. MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311-328 (2010).
12. Kassis, A. I. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat. Prot. Dosimetry 143, 241-247 (2011).
13. Cornelissen, B. & Vallis, K. A. Targeting the nucleus: An overview of Auger-electron radionuclide therapy. Curr. Drug Discov. Technol. 7, 263-279 (2010).
14. DeNardo, G. L. et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94 (Suppl. 4), 1332-1348 (2002).
15. Strigari, L. et al. Dosimetry in nuclear medicine therapy: Radiobiology application and results. Q. J. Nucl. Med. Mol. Imaging 55, 205-221 (2011).
16. Fowler, J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18, 1261-1269 (1990).
17. Ling, C. C., Gerweck, L. E., Zaider, M. & Yorke, E. Dose-rate effects in external beam radiotherapy redux. Radiother. Oncol. 95, 261-268 (2010).
18. Wessels, B. W. et al. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 17, 1257-1263 (1989).
19. Williams, J. A., Edwards, J. A. & Dillehay, L. E. Quantitative comparison of radiolabeled antibody therapy and external beam radiotherapy in the treatment of human glioma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 24, 111-117 (1992).
20. Knox, S. J. Overview of studies on experimental radioimmunotherapy. Cancer Res. 55 (Suppl.), 5832s-5836s (1995).
21. Knox, S. J., Goris, M. L. & Wessels, B. W. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother. Oncol. 23, 111-117 (1992).
22. Sgouros, G., Knox, S. J., Joiner, M. C., Morgan, W. F. & Kassis, A. I. MIRD continuing education: Bystander and low dose-rate effects: Are these relevant to radionuclide therapy? J. Nucl. Med. 48, 1683-1691 (2007).
23. Boyd, M. et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J. Nucl. Med. 47, 1007-1015 (2006).
24. Mairs, R. J., Fullerton, N. E., Zalutsky, M. R. & Boyd, M. Targeted radiotherapy: Microgray doses and the bystander effect. Dose Response 5, 204-213 (2007).
25. Prise, K. M. & O'Sullivan, J. M. Radiation-induced bystander signalling in cancer therapy. Nat. Rev. Cancer 9, 351-360 (2009).
26. Pressman, D. & Korngold, L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 6, 619-623 (1953).
27. DeNardo, S. J. et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int. J. Cancer Suppl. 3, 96-101 (1988).
28. Press, O. W. et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224 (1993).
29. DeNardo, G. & DeNardo, S. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. Semin. Nucl. Med. 40, 136-144 (2010).
30. Buchegger, F., Press, O. W., Delaloye, A. B. & Ketterer, N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 13, 657-667 (2008).
31. Illidge, T. & Morschhauser, F. Radioimmunotherapy in follicular lymphoma. Best Pract. Res. Clin. Haematol. 24, 279-293 (2011).
32. Leahy, M. F. & Turner, J. H. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117, 45-52 (2011).
33. Palanca-Wessels, M. C. & Press, O. W. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 116 (Suppl.), 1126-1133 (2010).
34. Goldsmith, S. J. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin. Nucl. Med. 40, 122-135 (2010).
35. Witzig, T. E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463 (2002).
36. Kaminski, M. S. et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352, 441-449 (2005).
37. Fisher, R. I. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J. Clin. Oncol. 23, 7565-7573 (2005).
38. Link, B. K. et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study. J. Clin. Oncol. 28, 3035-3041 (2010).
39. Morschhauser, F. et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26, 5156-5164 (2008).
40. Press, O. W. et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol. 24, 4143-4149 (2006).
41. Kaminski, M. S. et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol. 23, 7985-7993 (2005).
42. Deshpande, S. V. et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in RAJI tumored mice. J. Nucl. Med. 29, 217-225 (1988).
43. Morschhauser, F. et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol. 28, 3709-3716 (2010).
44. O'Donoghue, J. A. Implications of nonuniform tumor doses for radioimmunotherapy. J. Nucl. Med. 40, 1337-1341 (1999).
45. O'Donnell, R. T. et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J. Nucl. Med. 40, 2014-2020 (1999).
46. Burke, J. M. et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 32, 549-556 (2003).
47. Lauter, A. et al. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. Br. J. Haematol. 148, 910-917 (2010).
48. Matthews, D. C. et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85, 1122-1131 (1995).
49. Pagel, J. M. et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 114, 5444-5453 (2009).
50. Ringhoffer, M. et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: Results of a phase I-II study. Br. J. Haematol. 130, 604-613 (2005).
51. Kotzerke, J., Bunjes, D. & Scheinberg, D. A. Radioimmunoconjugates in acute leukemia treatment: The future is radiant. Bone Marrow Transplant. 36, 1021-1026 (2005).
52. Schulz, A. S. et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood 117, 4642-4650 (2011).
53. Rosenblat, T. L. et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16, 5303-5311 (2010).
54. Jurcic, J. G. et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100, 1233-1239 (2002).
55. Meredith, R. F. et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5 (Suppl.), 3254s-3258s (1999).
56. Meredith, R. F. et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin. Cancer Res. 2, 1811-1818 (1996).
57. Robert, F., Busby, E. M. & LoBuglio, A. F. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: Clinical effects and hematologic toxicity. Cancer Biother. Radiopharm. 18, 317-325 (2003).
58. Tempero, M. et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial. J. Clin. Oncol. 15, 1518-1528 (1997).
59. Wong, J. Y. et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin. Cancer Res. 9, 5842-5852 (2003).
60. Ychou, M. et al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin. Cancer Res. 14, 3487-3493 (2008).
61. Behr, T. M. et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med. 38, 858-870 (1997).
62. Yu, B. et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: Influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J. Clin. Oncol. 14, 1798-1809 (1996).
63. Juweid, M. et al. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J. Nucl. Med. 38, 257-260 (1997).
64. Juweid, M. E. et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85, 1828-1842 (1999).
65. Wong, J. Y. et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin. Cancer Res. 5 (Suppl.), 3224s-3231s (1999).
66. Liersch, T. et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J. Clin. Oncol. 23, 6763-6770 (2005).
67. Tempero, M. et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: A phase I trial. Clin. Cancer Res. 6, 3095-3102 (2000).
68. Sharkey, R. M. et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 71, 2082-2096 (1993).
69. Verheijen, R. H. et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578 (2006).
70. Stewart, J. S. et al. Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int. J. Radiat. Oncol. Biol. Phys. 16, 405-413 (1989).
71. Stewart, J. S. et al. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int. J. Cancer Suppl. 3, 71-76 (1988).
72. Murtha, A. D. Review of low-dose-rate radiobiology for clinicians. Semin. Radiat. Oncol. 10, 133-138 (2000).
73. DeNardo, G. L. et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res. 50 (Suppl.), 1014s-1016s (1990).
74. Knox, S. J. et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6, 406-414 (2000).
75. Wilder, R. B. et al. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Eur. J. Nucl. Med. 23, 953-957 (1996).
76. Ning, S., Trisler, K., Wessels, B. W. & Knox, S. J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80 (Suppl.), 2519-2528 (1997).
77. Roberson, P. L. & Buchsbaum, D. J. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Res. 55 (Suppl.), 5811s-5816s (1995).
78. Pacilio, M. et al. A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Eur. J. Nucl. Med. Mol. Imaging 37, 862-873 (2010).
79. Flynn, A. A. et al. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: A comparative study using the linear-quadratic formulation. Int. J. Radiat. Biol. 77, 507-517 (2001).
80. Dewaraja, Y. K. et al. 131I-tositumomab radioimmunotherapy: Initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J. Nucl. Med. 51, 1155-1162 (2010).
81. Bardiès, M. & Buvat, I. Dosimetry in nuclear medicine therapy: What are the specifics in image quantification for dosimetry? Q. J. Nucl. Med. Mol. Imaging 55, 5-20 (2011).
82. Konijnenberg, M. From imaging to dosimetry and biological effects. Q. J. Nucl. Med. Mol. Imaging 55, 44-56 (2011).
83. Wahl, R. L. Tositumab and 131I therapy in non Hodgkin's lymphoma. J. Nucl. Med. 46 (Suppl. 1) 128S (2005).
84. Wiseman, G. A. et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94 (Suppl.), 1349-1357 (2002).
85. Ferrer, L. et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer 116 (Suppl.), 1093-1100 (2010).
86. Malek, E. et al. Dosimetry for fractionated ZevalinTM treatment as an initial therapy of follicular lymphoma. Eur. J. Nucl. Med. Mol. Imaging 37 (Suppl. 2), S237 (2010).
87. Lindén, O. et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11, 5215-5222 (2005).
88. Gruber, R. et al. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 60, 1921-1926 (2000).
89. DeNardo, G. L. et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol. 16, 3246-3256 (1998).
90. Goldsmith, S. et al. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC) [abstract]. J. Nucl. Med. 52 (Suppl. 1), 357 (2011).
91. Ocean, A. J. et al. Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC) [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a240 (2011).
92. Behr, T. M. et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 (Suppl.), 1373-1381 (2002).
93. Sharkey, R. M. & Goldenberg, D. M. Cancer radioimmunotherapy. Immunotherapy 3, 349-370 (2011).
94. Andersson, H. et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2-a phase I study. J. Nucl. Med. 50, 1153-1160 (2009).
95. Li, L. et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J. Neurosurg. 113, 192-198 (2010).
96. Quang, T. S. & Brady, L. W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58, 972-975 (2004).
97. Welt, S. et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14, 1787-1797 (1996).
98. Chérel, M., Davodeau, F., Kraeber-Bodéré, F. & Chatal, J. F. Current status and perspectives in alpha radioimmunotherapy. Q. J. Nucl. Med. Mol. Imaging 50, 322-329 (2006).
99. Zalutsky, M. R. Targeted radiotherapy of brain tumours. Br. J. Cancer 90, 1469-1473 (2004).
100. Borchardt, P. E., Yuan, R. R., Miederer, M., McDevitt, M. R. & Scheinberg, D. A. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63, 5084-5090 (2003).
101. Yong, K. & Brechbiel, M. W. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 40, 6068-6076 (2011).
102. Sabbatini, P. & Spriggs, D. R. Consolidation for ovarian cancer in remission. J. Clin. Oncol. 24, 537-539 (2006).
103. Oei, A. L. et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120, 2710-2714 (2007).
104. Alvarez, R. D. et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8, 2806-2811 (2002).
105. Shen, S. et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46, 642-651 (2005).
106. Shen, S., Forero, A., Meredith, R. F. & LoBuglio, A. F. Biodistribution and dosimetry of In-111/Y-90-HuCC49DeltaCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. Cancer Biother. Radiopharm. 26, 127-133 (2011).
107. Reardon, D. A. et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24, 115-122 (2006).
108. Zalutsky, M. R. et al. Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49, 30-38 (2008).
109. Akabani, G. et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: A phase II study. J. Nucl. Med. 46, 1042-1051 (2005).
110. Forero, A. et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104, 227-236 (2004).
111. Kraeber-Bodéré, F. et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J. Nucl. Med. 47, 247-255 (2006).
112. DeNardo, S. J. et al. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin. Cancer Res. 11, 7187s-7194s (2005).
113. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J. & Chatal, J. F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834 (2006).
114. Devizzi, L. et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J. Clin. Oncol. 26, 5175-5182 (2008).
115. Press, O. W. et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol. 7, 1027-1038 (1989).
116. Richman, C. M. et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11, 5920-5927 (2005).
117. Sharkey, R. M. et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J. Nucl. Med. 46, 620-633 (2005).
118. Schliemann, C. & Neri, D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 180, 201-216 (2010).
119. Grana, C. et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br. J. Cancer 86, 207-212 (2002).
120. Riva, P. et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin. Cancer Res. 5 (Suppl.), 3275s-3280s (1999).
121. Nagengast, W. B. et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48, 1313-1319 (2007).
122. Abbas Rizvi, S. M. et al. Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. Cancer Biol. Ther. 7, 1547-1554 (2008).
123. Mattes, M. J. & Goldenberg, D. M. Therapy of human carcinoma xenografts with antibodies to EGFR and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur. J. Nucl. Med. Mol. Imaging 35, 1249-1258 (2008).
124. Sharkey, R. M., Press, O. W. & Goldenberg, D. M. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy. Blood 113, 3891-3895 (2009).
125. Milenic, D. E. et al. Improved efficacy of alpha-particle-targeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 116 (Suppl.), 1059-1066 (2010).
126. Wong, J. Y. Systemic targeted radionuclide therapy: Potential new areas. Int. J. Radiat. Oncol. Biol. Phys. 66 (Suppl.), S74-S82 (2006).
127. Demaria, S., Bhardwaj, N., McBride, W. H. & Formenti, S. C. Combining radiotherapy and immunotherapy: A revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63, 655-666 (2005).
128. Ruan, S. et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J. Nucl. Med. 41, 1905-1912 (2000).
129. Kinuya, S., Yokoyama, K., Michigishi, T. & Tonami, N. Optimization of radioimmunotherapy interactions with hyperthermia. Int. J. Hyperthermia 20, 190-200 (2004).
130. Koral, K. F. et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biother. Radiopharm. 15, 347-355 (2000).
131. Leonard, J. P. & Goldenberg, D. M. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26, 3704-3713 (2007).
132. Zhang, M. M. & Gopal, A. K. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin. Hematol. 45, 118-125 (2008).
133. Nademanee, A. et al. A phase 1/2 trial of high-dose yttrium-90- ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106, 2896-2902 (2005).
134. Illidge, T. M. et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113, 1412-1421 (2009).
135. Kaminski, M. S. et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329, 459-465 (1993).
136. Press, O. W. et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346, 336-340 (1995).
137. Davies, A. J. et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1469-1479 (2004).
138. Kaminski, M. S. et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol. 10, 1696-1711 (1992).
139. Pagel, J. M. et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107, 2184-2191 (2006).
140. Chong, G. et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin. Cancer Res. 11, 4818-4826 (2005).
141. Scott, A. M. et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 11, 4810-4817 (2005).
142. Welt, S. et al. Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study of monoclonal antibody A33. J. Clin. Oncol. 8, 1894-1906 (1990).
143. Meyer, T. et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 15, 4484-4492 (2009).
144. Wong, J. Y. et al. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J. Nucl. Med. 38, 1951-1959 (1997).
145. Shibata, S. et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin. Cancer Res. 15, 2935-2941 (2009).
146. Juweid, M. E. et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J. Nucl. Med. 41, 193-103 (2000).
147. Ychou, M. et al. Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: Pretherapeutic study with dose recovery in resected tissues. Eur. J. Cancer 29A, 1105-1111 (1993).
148. Sultana, A. et al. Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 9, 66 (2009).
149. Casey, J. L. et al. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: A clinical phase I/II study. Br. J. Cancer 86, 1401-1410 (2002).
150. Chatal, J. F. et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J. Clin. Oncol. 24, 1705-1711 (2006).
151. Sauer, S. et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113, 2265-2274 (2009).
152. Kramer, K. et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J. Clin. Oncol. 25, 5465-5470 (2007).
153. Divgi, C. R. et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J. Nucl. Med. 45, 1412-1421 (2004).
154. Oosterwijk, E. et al. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J. Clin. Oncol. 11, 738-750 (1993).
155. Divgi, C. R. et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. 4, 2729-2739 (1998).
156. Brouwers, A. H. et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23, 6540-6548 (2005).
157. Chen, Z. N. et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. Int. J. Radiat. Oncol. Biol. Phys. 65, 435-444 (2006).
158. Hird, V. et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 68, 403-406 (1993).
159. Meredith, R. F. et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. Nucl. Med. 36, 2229-2233 (1995).
160. Morris, M. J. et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11, 7454-7461 (2005).
161. Morris, M. J. et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res. 13, 2707-2713 (2007).
162. Vallabhajosula, S. et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med. 46, 850-858 (2005).
163. Vallabhajosula, S. et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin. Cancer Res. 11, 7195s-7200s (2005).
164. Meredith, R. F. et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J. Nucl. Med. 33, 23-29 (1992).